Endocyte
Clinical trials sponsored by Endocyte, explained in plain language.
Now part of
Novartis AG
NVS
NYSE
Biopharma developing targeted therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New radioactive therapy aims to control advanced prostate cancer Results expected Jan 2027 (estimated)